Does body mass index really predict the response to systemic therapies in metastatic melanoma: A multicenter study from the MelBase French National Cohort?
Y. Di Filippo(Inserm), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), O. Dereure(Beth Israel Deaconess Medical Center), Wendy Lefevre(Inserm), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), Henri Montaudié(Hôpital l'Archet), F. Brunet‐Possenti(Université Claude Bernard Lyon 1), E. Maubec(Délégation Paris 7), F. Aubin, Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Julie De Quatrebarbes(Centre Hospitalier Annecy Genevois), Pierre‐Emmanuel Stoebner(Centre Hospitalier Universitaire de Nîmes)
Cited by 1
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k